Details of issuance or disposal
Large-Scale Exercise of Series 22 Stock Acquisition Rights with Exercise Price Adjustment Clauses Issued through a Third-Party Allotment, End of the Exercise Period and Monthly Exercise Status
Number of shares delivered since the beginning of the month: 1,550,000 shares (1,550,000 new shares and 0 transferred treasury shares)
The lower thin line represents the existing number of shares to which these shares will be added.
Aggregate issue price of the Series 22 Stock Acquisition Rights: ¥4,450,000 (exercise prices of ¥148, ¥150, ¥152, ¥153 and ¥156, depending on the exercise date)
Exercise ratio relating to the exercise restriction based on the number of shares delivered since the beginning of the month: 9.7% (1,550,000 shares delivered across all series / 15,899,482 listed shares as of the payment date for the issuance)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
| Item | Details |
|---|---|
| Type of issuance or disposal | Large-Scale Exercise of Series 22 Stock Acquisition Rights with Exercise Price Adjustment Clauses Issued through a Third-Party Allotment, End of the Exercise Period and Monthly Exercise Status |
| Number of shares to be issued or disposed of | Number of shares delivered since the beginning of the month: 1,550,000 shares (1,550,000 new shares and 0 transferred treasury shares) |
| Total issue value | Aggregate issue price of the Series 22 Stock Acquisition Rights: ¥4,450,000 (exercise prices of ¥148, ¥150, ¥152, ¥153 and ¥156, depending on the exercise date) |
| Amount of funds to be raised | Amount of funds raised: ¥423,387,800 (estimated net proceeds: Not disclosed) |
| Intended allottee | Macquarie Bank Limited (total number issued: 89,000 rights) |
| Dilution Rate | Exercise ratio relating to the exercise restriction based on the number of shares delivered since the beginning of the month: 9.7% (1,550,000 shares delivered across all series / 15,899,482 listed shares as of the payment date for the issuance) |
| Total number of issued shares | 17,719,582 shares (as of the end of the month preceding the target month) → 19,269,582 shares (as of 14 September 2026) |
| Exercise price | ¥148, ¥150, ¥152, ¥153 and ¥156, depending on the exercise date. Details of the adjustment clauses and the adjustment floor: Not disclosed |
| Exercise period | Ended on 14 September 2026 (the period during which these Stock Acquisition Rights could be exercised ran through 14 September 2026) |
| Number of Stock Acquisition Rights | Total number issued: 89,000 rights; exercised: 26,701 rights; remaining unexercised: 62,299 rights |
| Reason for acquisition without consideration | Scheduled to acquire all of these Stock Acquisition Rights on 15 September 2026 and cancel all of them immediately after acquisition |
| Procedures under the Corporate Code of Conduct | Disclosed the status of compliance with the exercise restrictions under Article 434 of the Listing Regulations. The exercise ratio relating to the exercise restrictions was 9.7%. |
| Most recent equity financing | 7 May 2026: Issuance of Series 22 Stock Acquisition Rights. Aggregate issue price: ¥4,450,000; amount paid in through exercise: ¥418,937,800; total funds raised: ¥423,387,800 |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The monthly exercise status was disclosed because the number of rights exercised since the beginning of the month reached at least 10% of the total number issued. In addition, all of these Stock Acquisition Rights are scheduled to be acquired and cancelled on 15 September 2026, and the exercise period has ended.